Clinical Trial Update: Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours [Phase 3]

View source ↗

Summary

Phase 3 trial comparing osimertinib (AZD9291) plus durvalumab (MEDI4736) versus osimertinib alone in EGFR T790M-positive non-small cell lung cancer; results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or Metastatic EGFR T790M+ NSCLC | Phase 3 | Status: COMPLETED | Results posted: 2018-08-10